Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.

It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.

The company was incorporated in 2002 and is headquartered in Laval, Canada.